Immuno-Oncology | Specialty

Dr. Herbst on TMB as a Biomarker in NSCLC

August 3rd 2018

Roy S. Herbst, MD, PhD, professor of medicine, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses tumor mutational burden (TMB) as a biomarker in non–small cell lung cancer (NSCLC).

Dr. Wakelee on Single-Agent Immunotherapy in NSCLC

August 2nd 2018

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses single-agent immunotherapy in patients with non–small cell lung cancer (NSCLC).

Early Pembrolizumab/Bevacizumab Study Shows Promise in RCC

August 2nd 2018

Shilpa Gupta, MD, discusses the tolerability and safety of pembrolizumab and bevacizumab in renal cell carcinoma, as well as the future of bladder cancer treatment in the neoadjuvant setting.

FDA Grants Breakthrough Status to Lenvatinib/Pembrolizumab for Endometrial Cancer

August 2nd 2018

The FDA has granted a breakthrough therapy designation to the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) for the treatment of patients with advanced and/or metastatic non–microsatellite instability high/proficient mismatch repair endometrial carcinoma who have progressed after ≥1 prior systemic therapy.

Adjuvant Nivolumab Approved in Europe for Melanoma

July 31st 2018

The European Commission has approved nivolumab (Opdivo) as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease, regardless of BRAF mutation status.

Dr. Makker on Unmet Needs for Patients with Advanced Endometrial Cancer

July 31st 2018

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses unmet needs and treatment challenges for patients with advanced endometrial cancer.

Pembrolizumab Nears European Approval for HNSCC

July 31st 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab (Keytruda) for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma who progressed following platinum-based chemotherapy and have a PD-L1 tumor proportion score ≥50%.

EU Panel Backs Frontline Pembrolizumab Combo for Nonsquamous NSCLC

July 30th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of frontline pembrolizumab (Keytruda) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 expression.

Frontline Immunotherapy Poses Fresh Dilemma for Sequencing in NSCLC

July 29th 2018

As the checkpoint inhibitors move into the frontline setting for patients with non–small cell lung cancer, the focus has been placed on the duration of therapy and what to do in the second-line setting following progression.

Dr. Herbst on Intriguing Immunotherapy Combinations in NSCLC

July 28th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses immunotherapy combinations that have potential in non-small cell lung cancer (NSCLC).

Immunotherapy Combos Rapidly Evolving for Lung Cancer

July 28th 2018

The past year has witnessed an explosion in immunotherapy combinations for patients with lung cancer, accompanied by a growing knowledge of biomarkers such as PD-L1 and tumor mutation burden; however, an exact standard of care remains elusive.

Dr. Bunn on Immunotherapy Advances in Small Cell Lung Cancer

July 27th 2018

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care

Dr. Shunyakov on the Impact of Genomics on Personalized Therapy in Oncology

July 27th 2018

Leonid Shunyakov, MD, hematologist/oncologist, Central Care Cancer Center, discusses how genomics have impacted personalized therapy in oncology.

Durvalumab Approaches EU Approval for Locally Advanced PD-L1+ NSCLC

July 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy and whose tumors express PD-L1 on ≥1% of tumor cells.

Immunotherapy Requires Precision Medicine Approach for NSCLC

July 27th 2018

Immunotherapy should be given as a tailored, not blanket, treatment approach, especially for patients with lung cancer, according to Giorgio Scagliotti, MD, PhD.

Dr. Lynch on the Immuno-Oncology Network at Bristol-Myers Squibb

July 27th 2018

Thomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses the Immuno-Oncology (IO) Network at Bristol-Myers Squibb.

Dr. Bauml on Emerging Biomarkers in NSCLC

July 27th 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses emerging biomarkers in non–small cell lung cancer (NSCLC).

Dr. Konstantinopoulos on Rationale for TOPACIO Trial in Ovarian Cancer

July 25th 2018

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the rationale behind the TOPACIO trial for the treatment of patients with recurrent ovarian cancer.

Dr. Nghiem on Immunotherapy in Merkel Cell Carcinoma

July 25th 2018

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses immunotherapy for the treatment of Merkel cell carcinoma.

Frontline Pembrolizumab Improves Survival in HNSCC

July 25th 2018

Pembrolizumab (Keytruda) significantly improved overall survival compared with the standard frontline regimen of cetuximab (Erbitux) plus platinum chemotherapy and 5-FU in patients with recurrent or metastatic HNSCC.